Newstral
Article
jdsupra.com on 2018-11-28 22:49
European Commission Approves Pegfilgrastim Biosimilars
Related news
- FDA Approves Sandoz’s Biosimilar Pegfilgrastimjdsupra.com
- European Biosimilar Approval Updates: Adalimumab, Pegfilgrastimjdsupra.com
- European Commission invites targeted stakeholders for consultation on duplicate marketing authorisations for biological medicinal products and biosimilarsjdsupra.com
- Sandoz Initiates Declaratory Judgment Action Against Amgen Concerning Manufacturing of Filgrastim and Pegfilgrastim Biosimilarsjdsupra.com
- FDA Approves Second Pegfilgrastim Biosimilar, a First for Coherusjdsupra.com
- European Commission Approves Acquisition of Sole Control of OLSA by MAGNAjdsupra.com
- European Commission Approves UK Emergency State Aid for SMEs Affected by COVID-19jdsupra.com
- DEAL WATCH: Biosimilars, Biosimilars and More Biosimilarsjdsupra.com
- Russian Pharma Company Biocad Obtains European Certification for Biosimilars to Treat Cancerjdsupra.com
- European Commission Publishes Commission Delegated Regulation Amending Auctioning Allowances Rulesjdsupra.com
- European Commission Publishes 2020 Work Programmejdsupra.com
- European Commission Adopts Adequacy Decision for Japanjdsupra.com
- European Commission Releases Pharmaceutical Anti-Competition Reportjdsupra.com
- European Commission Communicates on Financial Services Equivalencejdsupra.com
- European Commission Presents Digital Tax Packagejdsupra.com
- European Commission Announces Work Plan for 2019jdsupra.com
- European Commission Announces New Bioeconomy Strategyjdsupra.com
- A guide to the new European Commissionjdsupra.com
- European Parliament Approves Resolution on Artificial Intelligencejdsupra.com
- European Commission approves transatlantic data-transfer frameworkjdsupra.com